Getting Credit for Being Old (It’s About Time)

Every week, I receive an email from a friend that’s filled with cartoons, jokes, and quirky one-liners. And this time around, one quip struck me as feeling eerily true: “It feels weird being the same age as old people.” Why? Well, like most folks who share my age (I’m 69),…

Researchers at QurAlis have discovered a molecule with the potential to act as a treatment for amyotrophic lateral sclerosis (ALS), in addition to a new therapeutic target for the disease. The findings from both projects were presented at the 31st International Symposium on ALS/MND,…

A method that measures tiny amounts of aggregated TDP-43 protein in the cerebrospinal fluid may have the potential to detect amyotrophic lateral sclerosis (ALS) in the early stages of the disease, potentially before symptom onset, a study reports. The study,…

Target ALS is launching an expansive $15 million research initiative aimed at discovering biomarkers and developing new scientific resources for amyotrophic lateral sclerosis (ALS). The Target ALS Diagnosis Initiative, touted as the first of its kind, will create grants and scientific resources to identify needed biomarkers. Such indicators allow…

It’s time again to send our annual Christmas letter and picture card to our friends and family. Since my daughter could talk, I’ve kept a list of cute things the kids say throughout each year. I pick the best to include in our letter. When Sara was 2, we…

Cytokinetics is preparing a global Phase 3 trial that will enroll more than 500 people with early amyotrophic lateral sclerosis (ALS) to test its investigational therapy reldesemtiv in slowing progressive muscle weakness, the company announced. Details from the trial design were shared at the 31st International Symposium…

“All the world’s a stage, And all the men and women merely players; They have their exits and their entrances; And one man in his time plays many parts …” – William Shakespeare Some months back, I…

The anticonvulsant ezogabine can significantly reduce abnormal motor neuron excitability in people with amyotrophic lateral sclerosis (ALS), a clinical trial has found. The findings support further investigation of ezogabine, and into the possible utility of neuron excitability as a measurement of disease in ALS, researchers…

One of the first symptoms of ALS I experienced was a sudden weakness in my legs and feet. This meant that without warning, whenever I walked I felt as if I had stepped in a hole, and more than once I ended up taking a nasty fall. Even when I…

Actimed Therapeutics has obtained the rights to develop and commercialize ACM-002 (S-oxprenolol) for the treatment of amyotrophic lateral sclerosis (ALS) in Europe, the company announced. The rights, licensed from patent owner Charité University Medicine Berlin, cover all major European markets, including France, Germany, the U.K., Italy,…